This study looks at 168 people with multidrug-resistant HIV who have few treatment options. It compares those who receive the drug ibalizumab plus other HIV medicines to those who do not. The goal is to see how well ibalizumab controls the virus over time and how safe it is in re…
Sponsor: Theratechnologies • Aim: Disease control
Last updated May 18, 2026 11:59 UTC